XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Intangible Asset (Tables)
3 Months Ended
Mar. 31, 2021
Intangible Asset  
Schedule of gross carrying amount and accumulated amortization of the Nucynta Intangible Asset

As of March 31, 

As of December 31, 

2021

2020

Gross carrying amount

$

521,170

$

521,170

Accumulated amortization

(202,061)

 

(185,266)

Intangible asset, net

$

319,109

$

335,904

Summary of costs included in acquired asset

Acquisition consideration:

Base purchase price

$

375,000

Cash paid for inventory

6,030

Transaction costs

6,297

Reduction for 2020 cash transferred to Assertio under the prior Nucynta Commercialization Agreement(1)

(13,071)

Reduction for accrued royalty obligation discharged upon closing(1)

(1,145)

Total acquisition consideration:

$

373,111

(1)Represents $14,216 total reduction to the base purchase price comprising of $13,071 of cash payments transferred to Assertio under the prior Nucynta Commercialization Agreement as well as a reduction for discharged pre-acquisition accrued royalties based on sales from January 1, 2020 through closing.

The Company then allocated the consideration transferred to the individual assets acquired on a relative fair value basis as summarized in the table below:

Assets acquired:

Nucynta Intangible Asset

$

367,081

Inventory

6,030

Total consideration allocated to assets acquired:

$

373,111

Summary of the gross carrying amount, accumulated amortization, and net book value

Gross Carrying Value

Accumulated Amortization

Net Book Value

Balance as of December 31, 2019

$

154,089

$

(124,586)

$

29,503

Amortization expense through Nucynta Acquisition

(1,754)

(1,754)

Additional cost incurred from Nucynta Acquisition

367,081

367,081

Amortization expense from Nucynta Acquisition through period end

(58,926)

(58,926)

Balance as of December 31, 2020

$

521,170

$

(185,266)

$

335,904

Amortization expense

(16,795)

(16,795)

Balance as of March 31, 2021

$

521,170

$

(202,061)

$

319,109

Summary of amortization expense

Three months ended March 31, 

2021

 

2020

Nucynta amortization expense included in cost of product revenues

$

16,795

$

10,295

Schedule of future amortization expenses

Years ended December 31,

Amortization Expense

2021

$

50,386

2022

67,181

2023

67,181

2024

67,181

2025

67,180

Remaining amortization expense:

$

319,109